Not enough injecting drug users (IDUs) are accessing antiretroviral drugs (ARVs), two international AIDS NGOs said on Monday.
Releasing their 'Joint Position Paper on Injecting Drug Users and Access to HIV Treatment', the Global Network of People living with HIV/AIDS (GNP+) and the International Community of Women Living with HIV/AIDS, attributed 10 percent of all new global HIV infections to injecting drug use.
IDUs currently represent only 7 percent of all people benefiting from global anti-AIDS treatment programes.
The organisations charged that current repressive drug policies were among the main obstacles to adequate access to HIV prevention and treatment programmes for IDUs.
"We believe that being an active drug user is not a valid criterion for denying an individual access to treatment and care," said Mauro Guarinieri, GNP+ chairman in a statement.
This article was produced by IRIN News while it was part of the United Nations Office for the Coordination of Humanitarian Affairs. Please send queries on copyright or liability to the UN. For more information: https://shop.un.org/rights-permissions
Help us be the transformation we’d like to see in the news industry
The current journalistic model is broken: Audiences are demanding that the hierarchical, elite-led system of news-gathering and presentation be dismantled in favour of a more inclusive and holistic model based on more equitable access to information and more nuanced and diverse narratives.
The business model is also broken, with many media going bankrupt during the pandemic – despite their information being more valuable than ever – because of a dependence on advertisers.
Finally, exploitative and extractive practices have long been commonplace in media and other businesses.
We think there is a better way. We want to build something different.
Our new five-year strategy outlines how we will do so. It is an ambitious vision to become a transformative newsroom – and one that we need your support to achieve.
Become a member of The New Humanitarian by making a regular contribution to our work - and help us deliver on our new strategy.